TRACON Pharmaceuticals is a biotechnology business based in the US. TRACON Pharmaceuticals shares (TCON) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.03 – a decrease of 48.28% over the previous week. TRACON Pharmaceuticals employs 17 staff and has a trailing 12-month revenue of around $3.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.03 |
|---|---|
| 52-week range | $0.02 - $14.75 |
| 50-day moving average | $0.09 |
| 200-day moving average | $1.81 |
| Wall St. target price | $6.00 |
| PE ratio | 0.01 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $5.93 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0295 from 2024-11-19
| 1 week (2024-11-13) | -49.14% |
|---|---|
| 1 month (2024-10-18) | -56.87% |
| 3 months (2024-08-20) | -73.18% |
| 6 months (2024-05-20) | -97.95% |
| 1 year (2023-11-20) | -83.00% |
|---|---|
| 2 years (2022-11-18) | -99.89% |
| 3 years (2021-11-19) | 51.8 |
| 5 years (2019-11-20) | 73.2 |
Valuing TRACON Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TRACON Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TRACON Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, TRACON Pharmaceuticals shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $3.2 million |
|---|---|
| Gross profit TTM | $-13,888,000 |
| Return on assets TTM | -59.37% |
| Return on equity TTM | -1277.01% |
| Profit margin | 162.34% |
| Book value | $-0.91 |
| Market Capitalization | $202,071 |
TTM: trailing 12 months
We're not expecting TRACON Pharmaceuticals to pay a dividend over the next 12 months.
TRACON Pharmaceuticals's shares were split on a 1:20 basis on 9 April 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TRACON Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for TRACON Pharmaceuticals shares which in turn could have impacted TRACON Pharmaceuticals's share price.
Over the last 12 months, TRACON Pharmaceuticals's shares have ranged in value from as little as $0.021 up to $14.746. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TRACON Pharmaceuticals's is 1.422. This would suggest that TRACON Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
TRACON Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co. , Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.